ChemoTech has developed a new patented treatment technology platform that is today used in two commercial product lines for the treatment of tumours in both humans and animals.
ChemoTech is dedicated to developing and marketing cost-effective, innovative solutions for tumour treatment in both humans and animals. Our goal is to create less destructive therapies that improve quality of life and extend life expectancy for the global population.
Our technology TSE (Tumour Specific Electroporation™) minimizes tumour necrosis and preserves healthy tissue by promoting apoptosis. Unlike traditional methods, it avoids burning or coagulation, enabling natural cell death. Through advanced hardware and software, TSE adapts the energy levels to each tumour’s unique characteristics. It boosts the efficacy of low doses of anti-cancer drugs while activating the immune system, providing an effective cancer treatment with fewer destructive side effects.
Within Human Care, our primary market for superficial tumours is India, with secondary prospective markets in the Middle East, Asia, Southeast Asia, and Africa—regions with significant needs and limited access to alternative, cost-effective treatment methods.
IQwave™, is the first CE-marked product developed and produced with the TSE technology.
TSE technology is well suited to treating tumours in sensitive areas where surgery is not possible, such as head and neck tumours. It can be used as primary treatment or combined with surgery to shrink the tumour and/or treat unclean margins. The technology can also be used before surgery to facilitate surgery, during radiotherapy, and for palliative care.
In summary, TSE:
There is growing evidence that TSE using IQwave™ and the published D-EECT protocol enhances the efficacy and safety of electrochemotherapy (ECT) approaches to the treatment of solid tumours.
TSE increases the effect of chemotherapy even at a lower dose, compared to traditional treatments, and enables the treatment of tumours that normally do not respond to chemotherapy. TSE delivers a carefully monitored energy to minimize tissue death while maximizing treatment efficacy and activating the immune system through apoptosis and release of a specific tumour antigen; an area that we will place great emphasis on in future clinical development.
Adapting and calibrating the technology, to be powerful enough to treat the tumour without generating destruction and ablation of healthy tissue is central to the TSE technology.
Get in touch
Are you interested in our products?
Our team is here to help with any questions about our products, patents or anything else you may need help with.
This website uses cookies. If you continue to browse the website, you agree to the use of cookies.